Meeting
2019 Genitourinary Cancers Symposium
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
Authors
Matthew Labriola
Duke Medical Center, Durham, NC
Matthew Labriola , Jason Zhu , Rajan Gupta , Shannon McCall , Jennifer Jackson , James R White , Elizabeth Weingartner , Eric Kong , Peter Simone , Eniko Papp , Kelly Gerding , John Simmons , Daniel J. George , Tian Zhang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 589)
DOI
10.1200/JCO.2019.37.7_suppl.589
Abstract #
589
Poster Bd #
F6
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase II trial of rucaparib (Without ADT) in patients with metastatic hormone-sensitive prostate cancer harboring germline DNA repair gene mutations (TRIUMPH).
First Author: Mark Christopher Markowski
Poster
2019 ASCO Annual Meeting
DNA damage response and repair (DDR) gene mutations and correlation with tumor mutation burden (TMB) in non-small cell lung cancer (NSCLC).
First Author: Hirva Mamdani
First Author: Saiama Naheed Waqar
Poster
2023 ASCO Annual Meeting
The spectrum of homologous recombination deficiency in cervical cancer: Is it also a cervical issue?
First Author: Muhammad Danyal Ahsan